Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.

Kaneko M, Narukawa M

The Annals of pharmacotherapy9 Feb 2018Cited by 7 (Europe PMC)

PMID29424239DOI10.1177/1060028018757407PepBankPUB-29424239

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in the LEADER trial, liraglutide increased restricted mean event-free survival time by 20 days versus placebo for the primary composite cardiovascular endpoint over 1620 days follow-up.
In plain wordsIn adults with type 2 diabetes, people on liraglutide stayed free of major heart events about 20 days longer than people on placebo.
Peptide
Liraglutide
Outcome
IncreaseDifference in restricted mean survival time, primary composite cardiovascular endpoint (LEADER)
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
RMST difference
20 days
LEADER, liraglutide minus placebo
Source sentences
Summary
20 days [6, 34] in LEADER (1620 days follow-up)
3 context sentences(design, population, supporting numbers)
Summary · context
The differences of RMSTs (GLP-1 receptor agonist minus placebo: point estimate and 95% CI) for primary composite endpoint of cardiovascular events were
Summary · context
Liraglutide and semaglutide decrease the risk of major adverse cardiovascular events compared with placebo when using the difference in RMST.
Summary · context
We used the difference in restricted mean survival time (RMST) as a measure of cardiovascular risks.
Report a problemFND-2942423901
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in the SUSTAIN-6 trial, semaglutide increased restricted mean event-free survival time by 8 days versus placebo for the primary composite cardiovascular endpoint over 672 days follow-up.
In plain wordsIn adults with type 2 diabetes, people on semaglutide stayed free of major heart events about 8 days longer than people on placebo.
Peptide
Semaglutide
Outcome
IncreaseDifference in restricted mean survival time, primary composite cardiovascular endpoint (SUSTAIN-6)
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
RMST difference
8 days
SUSTAIN-6, semaglutide minus placebo
Source sentences
Summary
8 days [1, 15] in SUSTAIN-6 (672 days follow-up)
3 context sentences(design, population, supporting numbers)
Summary · context
The differences of RMSTs (GLP-1 receptor agonist minus placebo: point estimate and 95% CI) for primary composite endpoint of cardiovascular events were
Summary · context
Liraglutide and semaglutide decrease the risk of major adverse cardiovascular events compared with placebo when using the difference in RMST.
Summary · context
We used the difference in restricted mean survival time (RMST) as a measure of cardiovascular risks.
Report a problemFND-2942423902

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) showed no substantial differences from placebo in other cardiovascular outcomes.
In plain wordsIn adults with type 2 diabetes, GLP-1 receptor drugs as a group, including liraglutide, showed no clear difference from placebo in other heart outcomes.
Peptide
Liraglutide
Outcome
No significant changeOther cardiovascular outcomes, pooled GLP-1 receptor agonists
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
As for the risk of other cardiovascular outcomes, there were no substantial differences between GLP-1 receptor agonists and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials with the aim of evaluating the cardiovascular risks associated with glucagon-like peptide 1 (GLP-1) receptor agonists, lixisenatide, liraglutide, semaglutide, and exenatide, have been conducted.
Summary · context
We used the difference in restricted mean survival time (RMST) as a measure of cardiovascular risks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2942423903
04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) showed no substantial differences from placebo in other cardiovascular outcomes.
In plain wordsIn adults with type 2 diabetes, GLP-1 receptor drugs as a group, including semaglutide, showed no clear difference from placebo in other heart outcomes.
Peptide
Semaglutide
Outcome
No significant changeOther cardiovascular outcomes, pooled GLP-1 receptor agonists
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
As for the risk of other cardiovascular outcomes, there were no substantial differences between GLP-1 receptor agonists and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized clinical trials with the aim of evaluating the cardiovascular risks associated with glucagon-like peptide 1 (GLP-1) receptor agonists, lixisenatide, liraglutide, semaglutide, and exenatide, have been conducted.
Summary · context
We used the difference in restricted mean survival time (RMST) as a measure of cardiovascular risks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2942423904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 5Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 4
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 12:10 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.